文献速递泌尿生殖MR

韩国男性前列腺癌筛查中直接行双参数MRI的经验

Upfront Biparametric MRI for Prostate Cancer Screening: Experience in 618 Korean Men Outside of a Clinical Trial Setting.
PubMed 文献 · AJR Am J Roentgenol · 2026-09-23

本研究回顾性纳入618名韩国无症状男性(中位年龄61岁),在健康体检中直接行前列腺双参数MRI(bpMRI)筛查,并与模拟的PSA触发路径比较。结果显示直接MRI路径效率较低,支持在该人群继续使用PSA阈值筛查策略。

要点

  • PI-RADS 1或2者占86.6%,均未行活检,可直接避免进一步有创操作。
  • 直接MRI路径中仅1.5%检出临床有意义前列腺癌,PSA路径可避免90.0%的MRI检查。
  • 在PROSA合格子集中,PSA路径未漏诊任何临床有意义前列腺癌病例。

核心结论

  • 直接MRI路径在韩国男性健康体检中效率较低,支持继续使用传统PSA阈值筛查策略。
  • 人群差异应在将临床试验结果外推至其他环境前予以充分考虑。

研究设计与样本

  • 回顾性研究,纳入618名韩国无症状男性,中位年龄61岁,2024年6月至2026年4月自愿接受健康体检项目中的前列腺双参数MRI。
  • 受检者此前无PSA检测史,与bpMRI同次就诊时行PSA检测。
  • PI-RADS≥3者行活检咨询,结果与模拟PSA触发路径比较(PSA>3.0 ng/mL才行bpMRI)。
  • 在符合PROSA随机试验入组标准的子集中行敏感性分析(49–69岁男性或≥40岁且有前列腺癌家族史者)。

关键影像表现/征象

  • 618名受检者中535名(86.6%)评估为PI-RADS 1或2,均未行活检。
  • 83名(13.4%)评估为PI-RADS≥3,66名(10.7%)行活检。
  • 9名受检者(1.5%)诊断为临床有意义前列腺癌,其中8名PSA>3.0 ng/mL。

诊断标准与关键数值

  • 以PSA>3.0 ng/mL为阈值模拟PSA触发路径,可避免90.0%(556/618)的bpMRI检查。
  • PSA触发路径可避免69.9%(58/83)的活检咨询和70.2%(40/57)的无临床有意义前列腺癌活检。
  • PSA触发路径以漏诊1例临床有意义前列腺癌为代价。
  • 在PROSA合格子集(n=442)中,PSA触发路径可避免89.4%(395/442)的bpMRI检查。
  • PROSA子集中PSA触发路径可避免68.2%(45/66)的活检咨询和66.0%(31/47)的无临床有意义前列腺癌活检,且未漏诊任何5例临床有意义前列腺癌。

临床应用与阅片要点

  • 在韩国男性体检人群中,PI-RADS 1或2者可避免活检,提示bpMRI的阴性预测价值可用于减少不必要的活检。
  • 直接MRI筛查检出的PI-RADS≥3者中大部分PSA>3.0 ng/mL,提示PSA阈值可前置筛选高获益人群。
  • 将欧美临床试验中直接MRI筛查结论外推至亚洲人群时需考虑人群差异带来的效率变化。

局限性

  • 单中心回顾性设计,可能存在选择偏倚。
  • 未报告bpMRI的具体设备和场强、判读医生经验与一致性。
  • 未活检的PI-RADS 1或2受检者缺乏组织学确认,可能低估漏诊。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background: Literature supporting MRI for upfront prostate cancer screening in lieu of a traditional PSA-triggered strategy has been performed primarily within clinical trial settings in North American and European populations. Objective: To describe a single center's experience in performing upfront MRI for PCa screening in Korean men outside of a clinical trial setting. Methods: This retrospective study included 618 asymptomatic Korean men (median age, 61 years) who voluntarily underwent prostate biparametric MRI (bpMRI) from June 2024 to April 2026 as part of a health check-up program. Examinees lacked prior PSA testing and underwent such testing during the same visit as the bpMRI examination. Examinees assessed as PI-RADS ≥3 underwent consultation for biopsy. Outcomes were compared with a simulated PSA-triggered pathway, presuming bpMRI was performed only in examinees with PSA >3.0 ng/mL. Sensitivity analysis was performed in the subset of examinees who would have been eligible for the PROSA randomized trial comparing upfront-MRI and PSA-triggered screening (i.e., men 49-69 years old or ≥40 years old with a prostate cancer family history). Results: The 618 examinees had a median PSA of 0.98 ng/mL. A total of 535/618 (86.6%) examinees were assessed as PI-RADS 1 or 2, none of whom underwent biopsy. A total of 83/618 (13.4%) examinees were assessed as PI-RADS ≥3, 66/618 (10.7%) underwent biopsy, and 9/618 (1.5%) were diagnosed with clinically significant prostate cancer (csPCa). Sixty-two examinees, and eight of nine examinees with csPCa, had PSA >3.0 ng/mL. A simulated PSA-triggered pathway would have avoided 90.0% (556/618) of bpMRI examinations, 69.9% (58/83) of biopsy consultations, and 70.2% (40/57) of performed biopsies without csPCa, at expense of missing one examinee with csPCa. In the PROSA-eligible subset (n=442), the PSA-triggered pathway would have avoided 89.4% (395/442) of bpMRI examinations, 68.2% (45/66) of biopsy consultations, and 66.0% (31/47) of performed biopsies without csPCa, without missing any of five cases of csPCa. Conclusion: The findings indicate inefficiency of the upfront-MRI pathway in Korean men undergoing general health evaluations and support continued use of conventional PSA-gating screening in this population. Clinical Impact: Population-level differences should be carefully considered before extrapolating trial results to other settings.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Joo, Tse, Yoon, et al. Upfront Biparametric MRI for Prostate Cancer Screening: Experience in 618 Korean Men Outside of a Clinical Trial Setting. AJR Am J Roentgenol. 2026. PMID: 42776580. doi:10.2214/AJR.26.35694

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。